Mingchen Health Co.,Ltd. (SZSE:002919) Might Not Be As Mispriced As It Looks

It's not a stretch to say that Mingchen Health Co.,Ltd.'s (SZSE:002919) price-to-sales (or "P/S") ratio of 2.5x seems quite "middle-of-the-road" for Personal Products companies in China, seeing as it matches the P/S ratio of the wider industry. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

View our latest analysis for Mingchen HealthLtd

What Does Mingchen HealthLtd's Recent Performance Look Like?

Recent times have been quite advantageous for Mingchen HealthLtd as its revenue has been rising very briskly. It might be that many expect the strong revenue performance to wane, which has kept the share price, and thus the P/S ratio, from rising. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Mingchen HealthLtd's earnings, revenue and cash flow.

How Is Mingchen HealthLtd's Revenue Growth Trending?

In order to justify its P/S ratio, Mingchen HealthLtd would need to produce growth that's similar to the industry.

Taking a look back first, we see that the company grew revenue by an impressive 130% last year. The latest three year period has also seen an excellent 179% overall rise in revenue, aided by its short-term performance. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Comparing that recent medium-term revenue trajectory with the industry's one-year growth forecast of 22% shows it's noticeably more attractive.

With this information, we find it interesting that Mingchen HealthLtd is trading at a fairly similar P/S compared to the industry. Apparently some shareholders believe the recent performance is at its limits and have been accepting lower selling prices.

The Key Takeaway

While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

To our surprise, Mingchen HealthLtd revealed its three-year revenue trends aren't contributing to its P/S as much as we would have predicted, given they look better than current industry expectations. When we see strong revenue with faster-than-industry growth, we can only assume potential risks are what might be placing pressure on the P/S ratio. While recent revenue trends over the past medium-term suggest that the risk of a price decline is low, investors appear to see the likelihood of revenue fluctuations in the future.

Having said that, be aware Mingchen HealthLtd is showing 1 warning sign in our investment analysis, you should know about.

If these risks are making you reconsider your opinion on Mingchen HealthLtd, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.